Not Just Healthcare... Lifecare.
Torrent Pharma, the flagship Company of Torrent Group, with a turnover of Rs. 8005 Cr is one of the leading Pharma companies in the Country. We are the pioneers in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
Torrent Pharma has crossed many geographical boundaries with presence in more than 40 countries. The Company is ranked first amongst Indian Companies for having largest market share in Brazil and Germany.
Torrent Pharma, the flagship company of the Torrent Group, is one of the leading Pharma companies in India. Conceived as a small generic company in the early '70s by Late Shri U N Mehta, Torrent Pharma blazed a new trail in the Indian pharmaceuticals industry by successfully implementing the concept of niche marketing.
With significant presence in more than 40 countries, Torrent is all poised to spread wings across globe with strong technical capabilities and international accreditations. To enable strategic differentiation, Torrent Pharma’s international business is segregated into US, UK, Germany, Europe, Brazil and Rest of the World.
Presence in 40 +
News & Events
Torrent Pharma enters into licensing agreement with Medicine Patent Pool
Torrent Pharma enters into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment click here
Torrent Pharma to launch Molnupiravir under the brand name Molnutor® in India click here
Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19 click here
Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India click here
Glenmark & Torrent sign licensing agreement for co-marketing of Remogliflozin Etabonate click here